title: Effect of PD I administration on dopamine receptors mRNAs expression in the lesioned striatum of PD rat model.
abstract: To study the effect of PD I administration on dopamine receptors (DR1, DR2) mRNAs expression in the lesioned striatum of the PD rat model and confirm if PD I has the effect of dopamine receptor agonist. The PD rats with unilateral 6-hydroxydopamine lesioned were administrated with PD I, L-dopa methyl/benserazide, L-dopa methyl /benserazide/ PD I, normal saline respectively for 4 weeks and their behavioral changes were observed. Then the rats were sacrificed and RT-PCR technique was used to detect changes of dopamine receptors (DR1, DR2) mRNAs expression in the ipsilateral striatum 1 day after the last treatment. The results showed that treatment with PD I plus L-dopa resulted in a stable contralateral rotation behavior; treatment with L-dopa resulted in a progressively increased contralateral rotation behavior. Rotation behavior induced by anhydromorphine decreased with PD I or PD I plus L-dopa treatment. Treatment With L-dopa or PD I plus L-dopa, up-regulation of DR1 mRNA and down-regulation of DR2 mRNA were observed in the ipsilateral striatum which were more obvious than that treated with PD I or vehicle (P < 0.05). It was concluded that long-term treatment with PD I could alleviate the behavior of PD rats. PD I had no apparent effect on the dopamine receptors (DR1, DR2) mRNAs expression in the ipsilateral striatum and the PD I has no agonist effect on dopamine receptors.
authors.affiliation: Department of Neurology, Union Hospital, Tongji Medical College, Huzhong University of Science and Technology, Wuhan 430022, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Mei
authors.forename: Shenggang
authors.initials: S
authors.lastname: Sun
authors.forename: Xuebing
authors.initials: X
authors.lastname: Cao
mesh_terms: D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism; D018491:Dopamine Agonists / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000378:metabolism; D008517:Phytotherapy; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000096:biosynthesis* / Q000235:genetics; D017448:Receptors, Dopamine D2 / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D018491:Dopamine Agonists; D004365:Drugs, Chinese Herbal; D012333:RNA, Messenger; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2